MC38-hIL1β
Strain Information
Validation Data
Fig1. The anti-hIL1β mAb Canakinumab alone or in combination with Tecentriq significantly inhibited the growth of MC38-hIL1β tumors in C57mice, demonstrating that this model is suitable for evaluating the in vivo efficacy of anti-hIL1β mAb alone and in combination with PD-1/PD-L1 antibodies.
Fig. 2 Blinatumomab injections were repeated daily for 5 days and immune cells in the PB of mice after therapy were measured by flow cytometry.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
